根据人口学变量对CDK-4/6抑制剂治疗的患者进行治疗差异的评估
Sneha Rajendran1, Marina Petruzzi2, Dianxu Ren3
1Department of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Future oncology (London, England)
|January 27, 2025
概括
转移性乳腺癌 (MBC) 患者接受循环素依赖性激酶4和6抑制剂 (CDKi) 并有医疗补助保险的患者的生存结果更差. 这种差异与延迟开始治疗无关.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 药物经济学 药物经济学
背景情况:
- 人口因素对循环林依赖性激酶4和6抑制剂 (CDKi) 在转移性乳腺癌 (MBC) 的有效性的影响尚不清楚.
- 了解这些差异对于公平的癌症护理至关重要.
研究的目的:
- 调查人口因素与ER+MBC患者的一线CDKi治疗结果之间的关联.
- 识别治疗提供和有效性的潜在障碍或差异.
主要方法:
- 从2015年1月到2022年12月,对173名ER+MBC患者进行了回顾性审查,这些患者接受了第一线CDKi治疗.
- 数据抽象包括治疗开始的时间 (TTI),进展的时间 (TTP) 和整体存活率.
- 统计分析包括描述性,比较性和相关性方法,使用多变量生存模型.
主要成果:
- 在TTI或TTP中没有发现显著的人口差异.
- 与私人保险患者相比,在多变量分析中,医疗补助保险患者的整体存活时间明显较短.
- 没有发现治疗开始的延迟可以解释这种生存差异.
结论:
- 医疗补助保险状况与MBC患者接受CDKi治疗的结果较差,独立于治疗延迟.
- 个性化支持策略可能是必要的,以解决社会经济差异,并改善弱势患者群体的结果.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Comparing the Survival Analysis of Two or More Groups
134
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
134
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Survival Analysis
324
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
324
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K


